Table 2.
Cox proportional hazards model in amlodipine-treated subjects, stratified by CYP3A4 and CYP3A5 genotypes
| Model |
CYP3A4 A–392G (A/A or A/G vs. G/G) (n = 135) |
CYP3A4 T16090C (C/C or T/C vs. T/T) (n = 145) |
CYP3A5 A6986G (G/G or A/G vs. A/A) (n = 146) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| hazard ratio | 95% CI | p∗ | hazard ratio | 95% CI | p∗ | hazard ratio | 95% CI | p∗ | |
| Low MAP | |||||||||
| Overall | |||||||||
| Unadjusted | 0.92 | 0.56, 1.54 | 0.76 | 2.18 | 1.27, 3.76 | 0.005 | 0.81 | 0.50, 1.29 | 0.37 |
| Adjusted∗ | 0.81 | 0.48, 1.38 | 0.44 | 2.04 | 1.17, 3.56 | 0.01 | 0.99 | 0.60, 1.61 | 0.95 |
| Males | |||||||||
| Unadjusted | 1.01 | 0.45, 2.30 | 0.98 | 1.94 | 0.95, 4.20 | 0.07 | 0.84 | 0.42, 1.68 | 0.61 |
| Adjusted∗ | 1.10 | 0.46, 2.65 | 0.832 | 2.22 | 1.03, 4.79 | 0.04 | 0.85 | 0.42, 1.73 | 0.66 |
| Females | |||||||||
| Unadjusted | 0.87 | 0.43, 1.78 | 0.70 | 2.22 | 1.01, 5.01 | 0.05 | 1.06 | 0.50, 2.24 | 0.88 |
| Adjusted∗ | 0.67 | 0.31, 1.42 | 0.29 | 2.33 | 1.01, 5.40 | 0.05 | 1.20 | 0.55, 2.59 | 0.649 |
| Usual MAP | |||||||||
| Overall | |||||||||
| Unadjusted | 0.91 | 0.53, 1.56 | 0.72 | 0.81 | 0.49, 1.32 | 0.39 | 0.85 | 0.53, 1.37 | 0.51 |
| Adjusted∗ | 1.48 | 0.82, 2.69 | 0.19 | 0.77 | 0.46, 1.31 | 0.34 | 0.60 | 0.35, 1.02 | 0.06 |
| Males | |||||||||
| Unadjusted | 0.97 | 0.45, 2.10 | 0.94 | 0.77 | 0.39, 1.49 | 0.43 | 0.75 | 0.39, 1.42 | 0.38 |
| Adjusted∗ | 1.31 | 0.58, 2.93 | 0.51 | 0.82 | 0.46, 1.85 | 0.92 | 0.73 | 0.38, 1.38 | 0.32 |
| Females | |||||||||
| Unadjusted | 2.81 | 0.93, 5.59 | 0.07 | 0.95 | 0.46, 2.09 | 0.95 | 1.44 | 0.64, 3.21 | 0.38 |
| Adjusted∗ | 3.41 | 1.20, 9.64 | 0.02 | 1.39 | 0.59, 3.27 | 0.46 | 1.16 | 0.52, 2.60 | 0.72 |
p ≤ 0.05 bolded, marginal significance; p ≤ 0.016 significant after adjustment for three multiple comparisons.
∗
Adjustment for baseline MAP, average number of daily antihypertensive medications, age, gender (for combined male and female models) and/or serum creatinine.